Nifty Pharma – Back to the resistance of 8300-8400.
Will it be able to breakout. Will be on radar for coming few weeks.
The Top 2 weights
Sun Pharma – ( 23% Weight )
Dr Reddys – ( 17% Weight )
The Indian Trading Conclave goes live tomorrow - Speaking on a difficult topic but apt for current markets - Identifying Bottom & Breakout Formations.
Whatsapp Subscription to the Blog
As most of us now prefer to read/save articles/post through the mobile phone and whatsapp, we are also drifting towards whatsapp subscription to the blog.
This is free and what do you get
1) In this you will get an alert on whatsapp whenever a new article is posted on the website.
2) Interesting older articles from www.nooreshtech.co.in
3) Interesting links and reads from Analyse India
4) Technical Charts and more updates in your whatsapp
The frequency would be a few messages a week. Generally less than 7-10 in a week or 1-2 in a day.
Click on this link for Whatsapp Subscription - https://bit.ly/2IzLJYQ
Do save 7977801488 in your contacts to receive the updates.
or whatsapp subscribe to +91 79778 01488 to receive messages save the number in your contacts.
Those who would like to shift to whatsapp can unsubscribe from the email list.
For more about our ADVISORY SERVICES
Customized Advisory Services- http://www.nooreshtech.co.in/quickgains-premium/platinum-plus
Derivatives - http://www.nooreshtech.co.in/quickgains
DISCLOSURE Nooresh Merani
Securities covered above: All mentioned in the above post
SEBI Registration disclosure - Investment Adviser ( INA000002991)
Nooresh Merani and his family/associates/ analysts would have exposure in the securities mentioned in the above report/article.
Nooresh Merani and his family/associates/ analysts do not have any financial interest/beneficial ownership of more than 1% in the company covered by Analyst.
Nooresh Merani and his family/associates/ analysts have not received any compensation from the company/third party covered in the above report/article ever.
Nooresh Merani and his family/associates/ analysts has not served as an officer, director or employee of company covered in the report/article and has not been engaged in market-making activity of the company covered in the report/article.
The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision